Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Jan 2025

He Zhiwei, Zheng Dijie, Li Futang, Chen Liwen, Wu Changhao, Zeng Zhirui, Yu Chao

Abstract excerpt

The high prevalence of KRAS mutations in pancreatic cancer (PC) is widely acknowledged and results in the resistance of targeted ferroptosis therapy and immunotherapy. Herein, via a CRISPR/Cas9 library screen, the effects of ferroptosis agonists were increased in KRAS-mutant PC cells upon knockout of tropomodulin 3 (TMOD3), while these effects were not observed in KRAS-wild-type cells. Increased levels of TMOD3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Ferroptosis

Share to Immunotherapy

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 39531951
DOI: 10.1016/j.drup.2024.101171

Genes

TMOD3
KRAS
PC
ACSL4
ASCL4
ELK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4.PMID 39531951Read ↗

Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS proteinSemantic proximity Read ↗

MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis.Semantic proximity Read ↗

The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.Semantic proximity Read ↗

TRPML1 triggers ferroptosis defense and is a potential therapeutic target in AKT-hyperactivated cancerSemantic proximity Read ↗

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentSemantic proximity Read ↗

Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathwaySemantic proximity Read ↗

SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.Semantic proximity Read ↗

TMEM87A/EBP/7-DHC/7-DHD Axis Promotes Pancreatic Cancer Progression via Ferroptosis EvasionSemantic proximity Read ↗

DHHC7 palmitoylates KRAS4A and promotes mutant KRAS-driven pancreatic cancersSemantic proximity Read ↗

A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.Semantic proximity Read ↗

SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune MicroenvironmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.